Structural and Biophysical Properties of Farnesylated KRas Interacting with the Chaperone SmgGDS-558
Dennis J. Michalak, Bethany Unger, Ellen Lorimer, Alexander Grishaev, Carol Williams, Frank N. Heinrich, Mathias Losche
KRas is a small GTPase and membrane-bound signaling protein. Newly synthesized KRas is posttranslationally modified with a membrane-anchoring prenyl group. KRas chaperones are therapeutic targets in cancer due to their participation in trafficking oncogenic KRas to membranes. SmgGDS splice variants are chaperones for small GTPases with basic residues in their hypervariable domain (HVR), including KRas. SmgGDS-607 escorts pre-prenylated small GTPases, while SmgGDS-558 escorts prenylated small GTPases. We provide a structural description of farnesylated and fully processed KRas (KRas-FMe) in complex with SmgGDS-558 and define biophysical properties of this interaction. Surface plasmon resonance measurements on biomimetic model membranes quantified the thermodynamics of the interaction of SmgGDS with KRas, and small-angle X-ray scattering was used to characterize complexes of SmgGDS-558 and KRas-FMe structurally. Structural models were refined using Monte Carlo and molecular dynamics simulations. Our results indicate that SmgGDS-558 interacts with the HVR and the farnesylated C-terminus of KRas-FMe, but not its G-domain. Therefore, SmgGDS-558 interacts differently with prenylated KRas than prenylated RhoA, whose G-domain was found in close contact with SmgGDS-558 in a recent crystal structure. Using immunoprecipitation assays, we show that SmgGDS-558 binds the GTP-bound, GDP-bound, and nucleotide-free forms of farnesylated and fully processed KRas in cells, consistent with SmgGDS-558 not engaging the Gdomain of KRas. We found that the dissociation constant, d, for KRas-FMe binding to SmgGDS558 is comparable to that for the KRas complex with PDEδ, a well-characterized KRas chaperone that also does not interact with the KRas G-domain. These results suggest that KRas interacts in similar ways with the two chaperones SmgGDS-558 and PDEδ. Therapeutic targeting of the SmgGDS-558/KRas complex might prove as useful as targeting the PDEδ/KRas complex in KRasdriven cancers.
, Unger, B.
, Lorimer, E.
, Grishaev, A.
, Williams, C.
, Heinrich, F.
and Losche, M.
Structural and Biophysical Properties of Farnesylated KRas Interacting with the Chaperone SmgGDS-558, Biophysical Journal, [online], https://dx.doi.org/10.1016/j.bpj.2022.05.028
(Accessed March 1, 2024)